Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.
2.

Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis.

Jeitler K, Horvath K, Berghold A, Gratzer TW, Neeser K, Pieber TR, Siebenhofer A.

Diabetologia. 2008 Jun;51(6):941-51. doi: 10.1007/s00125-008-0974-3. Epub 2008 Mar 20. Review.

PMID:
18351320
3.

In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.

Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, Lepore G, Aragona M, Iori E, Valentini U, Del Prato S, Tiengo A, Buhr A, Trevisan R, Baritussio A.

Diabet Med. 2008 Mar;25(3):326-32. doi: 10.1111/j.1464-5491.2007.02365.x.

PMID:
18307459
4.

Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.

Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, Luzio S, Owens DR, Bolli GB, Fanelli CG.

Diabetes Care. 2007 Oct;30(10):2447-52. Epub 2007 Jul 10. Erratum in: Diabetes Care. 2008 Jan;31(1):188.

PMID:
17623819
5.

Standards of medical care in diabetes--2007.

American Diabetes Association..

Diabetes Care. 2007 Jan;30 Suppl 1:S4-S41. No abstract available.

PMID:
17192377
6.

The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.

Kilpatrick ES, Rigby AS, Atkin SL.

Diabetes Care. 2006 Jul;29(7):1486-90.

PMID:
16801566
7.

Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine.

Gerich J, Becker RH, Zhu R, Bolli GB.

Diabetes Technol Ther. 2006 Apr;8(2):237-43.

PMID:
16734552
8.

Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes.

Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, Shutler SD, Stephens JW, Home PD.

Diabet Med. 2006 Mar;23(3):285-92.

PMID:
16492212
9.

Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial.

Hoogma RP, Hammond PJ, Gomis R, Kerr D, Bruttomesso D, Bouter KP, Wiefels KJ, de la Calle H, Schweitzer DH, Pfohl M, Torlone E, Krinelke LG, Bolli GB; 5-Nations Study Group..

Diabet Med. 2006 Feb;23(2):141-7.

PMID:
16433711
10.

Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.

Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW; Insulin Aspart CSII/MDI Comparison Study Group..

Diabetes Care. 2005 Mar;28(3):533-8.

PMID:
15735183
11.

Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin.

Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, Perriello G, Bolli GB.

Diabet Med. 2004 Nov;21(11):1213-20.

PMID:
15498088
12.

A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.

Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV.

Diabetes Care. 2004 Jul;27(7):1554-8.

PMID:
15220227
13.

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, Draeger E.

Diabetes. 2004 Jun;53(6):1614-20.

14.

Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump.

Garg SK, Walker AJ, Hoff HK, D'Souza AO, Gottlieb PA, Chase HP.

Diabetes Technol Ther. 2004 Feb;6(1):9-15.

PMID:
15000764
15.
18.

Insulins today and beyond.

Owens DR, Zinman B, Bolli GB.

Lancet. 2001 Sep 1;358(9283):739-46. Review. Erratum in: Lancet 2001 Oct 20;358(9290):1374.

PMID:
11551598
19.

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB.

Diabetes. 2000 Dec;49(12):2142-8.

PMID:
11118018
20.

Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.

Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini MG, Bartocci L, Brunetti P, Bolli GB.

Diabetes Care. 1999 Mar;22(3):468-77.

Supplemental Content

Support Center